Gothenburg, Sweden – Denator AB today announced that it has completed the fifth round of financing, raising a total of 12 million SEK The new shares have been subscribed by existing investors including T-bolaget, Wikow Ventures AB, SGP Group & Servisen Holding AB as well as new private investors. The financing round will strengthen Denator’s position in the protein research market by significantly increasing marketing and sales activities globally as well as focusing the product portfolio development for key markets.
Olof Sköld, CEO at Denator says: “We are very pleased to have secured this financing round which will be put towards an ambitious growth plan with new product launches next year. This funding is an important milestone in the commercial development of Denator and it will enable the company to continue its expansion.”
About Denator
Denator develops and sells products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques. Based upon the company’s proprietary heat- inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and maintain the stability of sample components throughout the analytical workflow. Established in 2004, Denator is headquartered at the Biotech Center in Gothenburg, Sweden. For more information visit: www.denator.com or contact:
Olof Sköld CEO Denator AB E-mail: olof@denator.com Tel.: +46 31 41 28 91 Fax.: +46 31 41 28 40
